BOND study: a randomised double-blind, placebo-controlled trial over 12 months to assess the effects of benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes with symptomatic polyneuropathy. Issue 2 (3rd February 2022)

• Record Type: Journal Article
• Authors: Bönhof, Gidon J; Sipola, Gundega; Strom, Alexander; Herder, Christian; Strassburger, Klaus; Knebel, Birgit; Reule, Claudia; Wollmann, Jan-Christoph; Icks, Andrea; Al-Hasani, Hadi; Roden, Michael; Kuss, Oliver; Ziegler, Dan
• Is Part Of: BMJ open. Volume 12:Issue 2(2022)
• Publication Date: 2022-02-03
• Subjects: diabetic neuropathy -- neuropathology -- diabetes & endocrinology -- diabetic foot; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2021-057142
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Introduction: Diabetic sensorimotor polyneuropathy (DSPN) affects approximately 30% of people with diabetes, while around half of cases are symptomatic. Currently, there are only few pathogenetically oriented pharmacotherapies for DSPN, one of which is benfotiamine, a prodrug of thiamine with a high bioavailability and favourable safety profile. While benfotiamine has shown positive effects in preclinical and short-term clinical studies, no long-term clinical trials are available to demonstrate disease-modifying effects on DSPN using a comprehensive set of disease-related endpoints. Methods and analysis: The benfotiamine on morphometric, neurophysiological and clinical measures in patients with type 2 diabetes trial is a randomised double-blind, placebo-controlled parallel group monocentric phase II clinical trial to assess the effects of treatment with benfotiamine compared with placebo in participants with type 2 diabetes and mild to moderate symptomatic DSPN. Sixty participants will be 1:1 randomised to treatment with benfotiamine 300 mg or placebo two times a day over 12 months. The primary endpoint will be the change in corneal nerve fibre length assessed by corneal confocal microscopy (CCM) after 12 months of benfotiamine treatment compared with placebo. Secondary endpoints will include other CCM measures, skin biopsy and function indices, variables from somatic and autonomic nerve function tests, clinical examination and questionnaires, general health, health-related quality of life, cost, safety and blood tests. Ethics and dissemination: The trial was approved by the competent authority and the local independent ethics committee. Trial results will be published in peer-reviewed journals, conference abstracts, and via online and print media. Trial registration number: DRKS00014832.